证券代码：600535 证券简称：天士力 编号：临 2025-025 号 天士力医药集团股份有限公司 关于增补部分董事、监事的公告 至第九届董事会任期届满时止。 2、增补部分独立董事 为保证公司法人治理结构完整，根据《公司法》、《公司章程》等有关规定， 经公司董事会提名、薪酬与考核委员会审核，公司第九届董事会第 7 次会议审议 通过了《关于增补公司第九届董事会部分独立董事的议案》，公司董事会提名段亚 林先生、徐宁先生、叶霖先生作为公司第九届董事会独立董事候选人（简历附后）， 独立董事任期自公司 2025 年第一次临时股东大会审议通过之日起至第九届董事 会任期届满时止。独立董事候选人提名已征得候选人本人同意，与公司不存在任 何关联关系，具备法律法规要求的专业性和独立性。 以上非独立董事、独立董事候选人将由公司 2025 年第一次临时股东大会采用 累积投票制选举产生，在公司股东大会审议通过前，原董事会成员仍依照《公司 法》、《公司章程》等有关规定，履行公司董事职务。 本公司董事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 ...

证券代码：600535 证券简称：天士力 编号：临 2025-027 号 天士力医药集团股份有限公司 关于修订《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步提升天士力医药集团股份有限公司（以下简称"公司"）规范运作 水平，完善公司治理结构，根据《公司法》《证券法》《上市公司章程指引》 《上海证券交易所股票上市规则》等法律法规、规范性文件的规定，结合公司实 际情况，拟对《公司章程》进行修订，修订情况如下： | 修订前 | 修订后 | | --- | --- | | 第八条 公司法人代表由董事长或者总 | 第八条 公司法定代表人由总经理担 | | 经理担任。 | 任。 | | 第十一条 本章程所称其他高级管理人 | 第十一条 本章程所称其他高级管理人 | | 员是指公司的董事会秘书、财务总监。 | 员是指公司的副总经理、财务总监、董事会 | | | 秘书和经公司董事会决定的其他高级管理 | | | 人员。 | | 第十二条 公司根据中国共产党章程的 | 第十二条 公司根据《中国共产党章程》 | ...

Group 1 - CIMC reported a net profit of RMB 29.72 billion for 2024, a year-on-year increase of 605.60% [1] - CIMC's revenue reached RMB 1,776.64 billion, up 39.01% from the previous year [1] - The container manufacturing segment generated revenue of RMB 622.05 billion, a 105.89% increase year-on-year [1] Group 2 - CIMC Vehicles reported revenue of RMB 209.98 billion, a decrease of 16.30% year-on-year [2] - Net profit for CIMC Vehicles fell to RMB 10.81 billion, down 55.83% compared to the previous year [2] - The decline in net profit was attributed to normalization of North American business and non-recurring gains from a previous equity disposal [2] Group 3 - SMIC's revenue for 2024 was RMB 57,795.6 million, an increase of 27.7% year-on-year [3] - The net profit for SMIC decreased by 23.3% to RMB 3,698.7 million [3] - The increase in revenue was driven by a rise in wafer sales volume, which increased by 36.7% [3] Group 4 - Haier Smart Home achieved a net profit of RMB 187.41 billion, a year-on-year increase of 12.92% [4] - The company reported revenue of RMB 2,859.81 billion, up 4.29% from the previous year [4] - The gross margin for Haier Smart Home was 27.8%, an increase of 0.3 percentage points from 2023 [4] Group 5 - CNOOC reported a net profit of RMB 137.94 billion for 2024, an increase of 11.4% year-on-year [6] - The company's revenue was RMB 420.51 billion, a slight increase of 0.9% from the previous year [6] - CNOOC's oil and gas production reached 199 million barrels of oil equivalent per day [6] Group 6 - CNOOC's oil liquid sales volume increased by 9.4% to 562.9 million barrels [7] - The average realized oil price was USD 76.75 per barrel, a decrease of approximately 1.6% [7] - The company achieved a reserve replacement rate of 167% with 11 new discoveries [7] Group 7 - China Merchants Securities reported a net profit of RMB 103.86 billion, an increase of 18.51% year-on-year [8] - The company achieved revenue of RMB 208.91 billion for the year [8] - Wealth management and institutional business contributed RMB 102.33 billion to the revenue [8] Group 8 - China Merchants Energy reported a net profit of RMB 51.07 billion for 2024 [9] - The company's revenue was RMB 257.99 billion, with a slight decrease of 0.32% [9] - The revenue decline was influenced by fluctuations in the oil tanker market [9] Group 9 - Industrial Bank achieved a net profit of RMB 772.05 billion, a year-on-year increase of 0.12% [11] - The bank's revenue was RMB 2,122.26 billion, up 0.66% from the previous year [11] - The non-performing loan ratio was 1.07%, indicating stable asset quality [11] Group 10 - Weichai Power reported a net profit of RMB 114.03 billion, a year-on-year increase of 26.51% [12] - The company's revenue reached RMB 2,156.9 billion, up 0.81% [12] - The sales of various engines totaled 734,000 units, with a 5% increase in exports [13] Group 11 - Lens Technology achieved a net profit of RMB 36.24 billion, a year-on-year increase of 19.94% [14] - The company reported revenue of RMB 698.97 billion, up 28.27% [14] - The smartphone and computer segments contributed significantly to revenue growth [14] Group 12 - Shandong Gold reported a net profit of RMB 29.52 billion, a year-on-year increase of 26.80% [15] - The company's revenue was RMB 825.18 billion, up 39.21% [15] Group 13 - Huadian International achieved a net profit of RMB 57.03 billion, a year-on-year increase of 26.11% [16] - The company's revenue was RMB 1,129.94 billion, a decrease of 3.57% [16] Group 14 - Postal Savings Bank reported a revenue of RMB 348.77 billion, a year-on-year increase of 1.83% [16] - The bank's net interest income was RMB 286.12 billion, up 1.53% [16] Group 15 - Joyoung reported a net profit of RMB 1.22 billion, a year-on-year decrease of 68.55% [17] - The company's revenue was RMB 8.85 billion, down 7.94% [17] Group 16 - Shanghai Pharmaceuticals achieved a net profit of RMB 45.53 billion, a year-on-year increase of 20.82% [18] - The company's revenue was RMB 2,752.51 billion, up 5.75% [18] Group 17 - CITIC Securities reported a net profit of RMB 72.23 billion, a year-on-year increase of 2.68% [19] - The company's revenue was RMB 211.29 billion, down 9.1% [19] Group 18 - Three squirrels plan to issue H-shares and apply for listing on the Hong Kong Stock Exchange [21] - The company aims to enhance global brand recognition and expand overseas financing capabilities [21] Group 19 - CIMC announced the termination of the spin-off of its subsidiary CIMC Tianda for listing on the Shenzhen Stock Exchange [22] - The decision was made for comprehensive considerations regarding business development and capital operation planning [22] Group 20 - CNOOC's subsidiary CIMC Tianda withdrew its IPO application [23] - The expected fundraising amount was RMB 1.41941 billion [23]

Group 1 - The core point of the announcement is the completion of the transfer of shares from Tianjin Tianshili Group and its concerted actors to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. and Guoxin Investment Co., Ltd., resulting in a change of control of Tianshili Pharmaceutical Group [1][2] - Tianjin Tianshili Group and its concerted actors transferred a total of 418,306,002 shares, representing 28% of the total share capital of Tianshili, to China Resources Sanjiu [1][5] - Guoxin Investment acquired 74,697,501 shares, accounting for 5% of the total share capital, as part of the agreement [2][5] Group 2 - Following the completion of the share transfer, the controlling shareholder changed from Tianjin Tianshili Group to China Resources Sanjiu, with the actual controller now being China Resources Limited [2][5] - After the transfer, Tianjin Tianshili Group and its concerted actors hold a total of 261,452,489 shares, which is 17.5008% of the total share capital [4][5] - Tianshili Group has committed to relinquishing voting rights corresponding to 5% of its shares, ensuring that the voting rights controlled do not exceed 12.5008% of the total issued shares [4][5]

生新任监事前，监事李江山先生将继续履行监事职务。公司将尽快完成相关董事及 监事人员的补选工作。 证券代码：600535 证券简称：天士力 编号：临 2025-022 号 天士力医药集团股份有限公司 关于部分董事、监事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 3 月 27 日，天士力医药集团股份有限公司（以下简称"天士力"或"公 司"）董事会和监事会分别收到董事长闫凯境先生、副董事长蒋晓萌先生、副董事长 孙鹤先生、董事蔡金勇先生、董事周水平先生、独立董事张斌先生以及监事会主席 鞠爱春先生、监事李江山先生、监事章顺楠先生递交的书面辞职报告。现将相关情 况公告如下： 2025 年 3 月 27 日，公司收到天士力生物医药产业集团有限公司（以下简称"天 士力产业集团"）发来的中国证券登记结算有限责任公司出具的《过户登记确认书》， 确认：（1）天士力产业集团及其一致行动人天津和悦科技发展合伙企业（有限合伙）、 天津康顺科技发展合伙企业（有限合伙）、天津鸿勋科技发展合伙企业（有限合伙）、 天津通明科技 ...

本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600535 证券简称：天士力 编号：临 2025-023 号 天士力医药集团股份有限公司 关于变更职工代表监事的公告 天士力医药集团股份有限公司（以下简称"公司"）监事会于 2025 年 3 月 26 日收到职工代表监事王贞女士、陆振先生的书面辞职报告，由于工作原因申请辞去 职工代表监事职务。王贞女士、陆振先生在担任公司职工代表监事期间恪尽职守、 勤勉尽责，公司监事会对两位职工代表监事为公司发展做出的贡献表示衷心感谢！ 根据《公司法》、《公司章程》等有关规定，公司于 2025 年 3 月 26 日进行职工 代表民主选举，推选马悦先生、高展先生为公司第九届监事会职工代表监事（简历 详见附件），任期自本次职工代表监事选举通过之日起至第九届监事会届满之日止。 特此公告。 2025 年 3 月 28 日 附件：职工代表监事简历 马悦，男，1981 年 7 月出生，本科毕业，管理学学士。2003 年至 2009 年分别 担任公司库房管理员、计划主管及采购主管，2010 年 ...

关于原控股股东及其一致行动人协议转让公司股份完成过户登记暨 控制权发生变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600535 证券简称：天士力 编号：临 2025-021 号 天士力医药集团股份有限公司 天士力医药集团股份有限公司（以下简称"天士力"或"公司"）于 2025 年 3 月 27 日收到原控股股东天士力生物医药产业集团有限公司（以下简称"天士力 集团"） 及其一致行动人发来的《中国证券登记结算有限责任公司证券过户登记 确认书》，获悉天士力集团及其一致行动人持有的天士力部分股份协议转让给华 润三九医药股份有限公司（以下简称"华润三九"）、国新投资有限公司（以下 简称"国新投资"）的过户登记手续已办理完毕。现将相关情况公告如下： 一、本次交易的基本情况 2024 年 8 月 4 日，公司控股股东天士力集团及其一致行动人天津和悦科技 发展合伙企业（有限合伙）、天津康顺科技发展合伙企业（有限合伙）、天津鸿 勋科技发展合伙企业（有限合伙）、天津通明科技发展合伙企业（有限合伙）、 天津顺祺科技 ...

天士力医药集团股份有限公司 2024 年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利 0.20 元 证券代码：600535 证券简称：天士力 编号：临 2025-020 号 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公 司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本 1,493,950,005 股为基数，每股派发现 金红利 0.20 元（含税），共计派发现金红利 298,790,001.00 元。 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | --- | --- | | Ａ股 | 2025/3/25 | － | 2025/3/26 | 2025/3/26 | 差异化分红送转： 否 一、通过分配方案的股东大会届次和日期 本次利润分配方案经公司 2025 年 3 ...

Core Viewpoint - China Resources Sanjiu's acquisition of 28% stake in Tianjin Tasly Pharmaceutical Group for 6.074 billion yuan aims to enhance its capabilities in traditional Chinese medicine innovation and integrate resources in the industry chain, channels, and brand [1] Transaction Purpose - The acquisition is intended to strengthen the research and development capabilities of traditional Chinese medicine, with a focus on complementing existing business in areas such as cardiovascular and oncology [1] Valuation Controversy - The transaction valuation used a single market method, pricing Tasly at 14.85 yuan per share, which is at the lower end of the valuation range (14.16-18.60 yuan). The Shenzhen Stock Exchange questioned the compliance of using only one valuation method [1] Competition Issues - Post-transaction, there will be competition between Tasly's retail business and China Resources Sanjiu's pharmaceutical operations. The company has committed to resolving this competition within five years through asset transfers and business integration [1] Goodwill Risk - The acquisition will add 2.611 billion yuan in goodwill, bringing the total goodwill for China Resources Sanjiu to 7.735 billion yuan. The company has indicated that if Tasly's performance does not meet expectations or if market conditions worsen, it may lead to goodwill impairment [1] R&D and Sales - Tasly plans to invest 1.039 billion yuan in R&D in 2024, with a capitalization rate of 20.11%, focusing on cardiovascular and oncology fields. The company asserts that its capitalization timing aligns with industry practices [1] - Tasly's sales expense ratio for 2024 is projected at 35.16%, higher than the industry average, primarily due to high costs associated with self-promotion and academic investments in prescription drugs [1] Overcapacity Production - Some of Tasly's products are reported to be produced beyond the approved environmental capacity, with a utilization rate of 193% for a specific product. The company has initiated expansion environmental assessment procedures and received a "no violation" certificate from local environmental authorities [1] Conclusion - The acquisition solidifies China Resources Sanjiu's position as a leader in the traditional Chinese medicine sector, but the significant increase in goodwill, rising debt levels, and overcapacity risks introduce uncertainties for future performance. The ability to realize synergies during integration will be a core challenge [1]

证券代码：600535 证券简称：天士力 编号：临 2025-018 号 天士力医药集团股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2025 年 3 月 27 日(星期四)至 4 月 1 日(星期二)16:00 前登录上证 路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 stock@tasly.com 进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 天士力医药集团股份有限公司（以下简称"公司"）已于 2025 年 3 月 4 日发 布公司 2024 年年度报告，为便于广大投资者更全面深入地了解公司 2024 年度经 营成果、财务状况，公司计划于 2025 年 4 月 2 日（星期三）下午 15:00-16:00 举行 2024 年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年度的经营成果及 财务指标的具体情况与投资者进行互动交流和沟通，在信息 ...